All In Biotech

Drug Trial Radar · NCT06471959

Psychedelic-assisted Group Program for First Responders

Assessing the Feasibility of a Custom Psychedelic-assisted Group Program on Mental and Physical Health in First Responders

Last checked: Nov 20, 2026Latest source record: Jun 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

32

Planned (sponsor's estimate)

Start

Jan 1, 2025

Primary completion

Jul 1, 2025

Study completion Sep 1, 2025

Sponsor

Lead sponsor
Empower Research IncIndustry
Sponsor type
Industry
Collaborators
Empower Psychedelics; Centre for Neurology Studies, Canada; Mitacs
First posted
Jun 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a two-group feasibility study of oral psilocybin combined with a 12-week group-based program, customized for firefighters. Trained facilitators will help create a trauma-informed space for the group (n = 6-8) to thrive and promote cognitive resilience. The topics covered throughout the 12 weeks include breath-work, mindfulness, self-compassion, embodiment, and Internal Family Systems work. Group 1 (control): 12-week group-based program, with a breathwork day at week 10 Group 2 (intervention): 12-week group-based program, with a 10mg dose of psilocybin (PEX010) at Week 10 Assessment timepoints: * Baseline * Mid-program (Week 6) * End of program (Week 12) * 6-month follow up

Conditions

  • Psilocybin
  • Psychotherapy, Group

Interventions

  • PsilocybinDrug

    Psilocybin in the study comes in the form of the study drug, PYEX. PYEX is a drug substance which is a partially purified fraction of the extract of Psilocybe cubensis mushroom fruiting bodies. It is a mixture of indole alkaloids, other mushroom fruiting body components and stabilization excipients. The major indole alkaloids present include psilocybin and psilocin (dephosphorylated psilocybin). PEX010 is a capsule for oral administration and is manufactured with PYEX (12.5-14.0% psilocybin), excipients, and HPMC (hydroxypropyl methyl cellulose) capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Target recruitment rateTime frame: Within 6 months
  2. Retention rateTime frame: Study Completion (8 months)
  3. Adherence to scheduleTime frame: Through Study completion (8 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Neurology Studies

    Surrey, British Columbia, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.